It is extremely important for clinicians treating MS to enhance their knowledge base about the changing landscape of the MS disease-modifying therapies (DMTs). Making treatment decisions for an individual MS patient is a daunting task and the individualized patient benefit-risk assessment becomes increasingly difficult as new therapies emerge. Furthermore, if these therapies become available, clinicians need to have a full understanding of their benefit-risk profiles. Faculty will review the efficacy and safety profiles of current and late-stage emerging MS DMTs.
It is equally challenging to define what constitutes optimal and suboptimal response to DMTs for an individual patient. Moreover, it is critical for clinicians to be able to recognize short-term clinical and paraclinical factors that may help identify patients at high risk for long-term disability. Faculty will review key considerations in MS clinical practice to address the above challenges in both didactic and case-based formats.
This program complements C190: Multiple Sclerosis Overview: Basic and Translational Science and C201: Multiple Sclerosis Overview: Clinical Pearls, but covers independent topics.
Participants should feel more confident in prescribing and monitoring multiple sclerosis (MS) disease-modifying therapies (DMTs) as it relates to their efficacy and safety profiles along with develop a better understanding of key considerations in clinical practice. Participants will also become familiar with late-stage DMTs that have a strong potential of getting approved for use in MS. Participants should also be able to recognize what factors put an MS patient at risk for long-term disability and when to consider switching therapies.
Medical Knowledge, Patient Care
Program Speakers - Tentative
3:30 PM - 4:30 PM
The Expanding Armamentarium of Multiple Sclerosis Therapeutics
Scott Douglas Newsome DO, FAAN
4:30 PM - 5:30 PM
Case-based Considerations in Clinical Practice for Multiple Sclerosis
Myla D. Goldman MD, MSC
Myla D. Goldman, MD, MSC
Dr. Goldman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with ADAMAS, EMD Serono, Sanofi Genzyme, Novartis Pharmaceutical, and Teva Neuroscience. Dr. Goldman has received research support from Biogen Idec, Novartis Pharmaceuticals, NIH, and National MS Society.